NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled
NCT05635266 2024-05-07Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesSanguine BiosciencesRecruiting20,000 enrolled
NCT02921828 2022-07-05A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCelgeneCompleted1,149 enrolled
NCT02921802 2022-06-14A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCelgeneCompleted4,626 enrolled
NCT02922543 2022-06-14A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCelgeneCompleted361 enrolled
NCT03406325 2020-04-09Mast Cell Activation Test in Allergic DiseaseHong Kong Sanatorium & HospitalCompleted19 enrolled 17 charts
NCT03858738 2019-03-04A Pilot Study on Use of Liquid Crystal Contact Thermography to Detect Early Breast CancerBraster S.A.Completed274 enrolled
NCT00288275 2012-10-05Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube CancerPrecision TherapeuticsTerminated256 enrolled